Higher-Dose Semaglutide 7.2 mg Achieves 18.7% Weight Loss at 72 Weeks — Nearly 3 Points More Than Standard Wegovy Dose

Semaglutide 2.4 mg (Wegovy) changed the obesity treatment landscape when STEP 1 reported 14.9% mean weight loss at 68 weeks — numbers that no prior anti-obesity medication had approached outside of bariatric surgery. But for a substantial fraction of patients, that is not enough. Obesity is a heterogeneous condition; a patient who enters treatment at a BMI of 42 and loses 15% reaches a BMI of 35.7 — still in Class II obesity, still carrying most of the metabolic burden. Novo Nordisk hypothesized that pushing semaglutide from 2.4 mg to 7.2 mg per week — a three-fold dose increase — might close more of that gap.[1, 2]

The STEP UP phase 3b randomized controlled trial enrolled 1,407 adults with obesity and no type 2 diabetes (mean age 47 years, 73.7% women, mean body weight 113 kg, mean BMI 39.9 kg/m²) and randomly assigned them to once-weekly subcutaneous semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo, alongside a lifestyle intervention program, for 72 weeks. There were two coprimary endpoints: mean percentage change in body weight at 72 weeks, and the proportion of participants achieving at least 5% body weight reduction versus placebo.[1]

On the first coprimary endpoint, semaglutide 7.2 mg produced a mean weight loss of 18.7%, compared with 15.6% for semaglutide 2.4 mg and 3.9% for placebo. The estimated treatment difference between the 7.2 mg and 2.4 mg doses was −3.1 percentage points (95% CI −4.7 to −1.6; P<0.0001), and versus placebo was −14.8 percentage points (95% CI −16.2 to −13.4; P<0.0001). The incremental benefit of the higher dose was consistent across weight-loss thresholds: at 20% or greater body weight reduction, 7.2 mg was more likely than 2.4 mg (OR 1.8; 95% CI 1.3–2.4) and far more likely than placebo (OR 27.3; 95% CI 10.9–68). At ≥25% weight reduction, 7.2 mg was twice as likely as 2.4 mg to produce that outcome (OR 2.4; 95% CI 1.6–3.5). By the end of the trial, 43.2% of participants receiving semaglutide 7.2 mg had reached a BMI below 30 kg/m².[1]

Clinical Context

The STEP program trials established semaglutide 2.4 mg as the benchmark for pharmacologic obesity treatment. STEP 1 (N=1,961; NEJM 2021) demonstrated 14.9% weight loss with semaglutide 2.4 mg versus 2.4% with placebo over 68 weeks. The SELECT trial (NEJM 2023) then showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease, converting an anti-obesity drug into a cardiovascular risk-reduction therapy. Meanwhile, tirzepatide (Zepbound) — which combines GLP-1 and GIP receptor agonism — showed 22.5% weight loss in the SURMOUNT-1 trial, raising the question of whether single-mechanism GLP-1 agonism had reached a ceiling, or whether dose escalation could extend the curve.[2, 3, 4]

STEP UP answers that question for semaglutide: the higher dose delivers meaningfully more weight loss than the approved 2.4 mg dose. The 3.1 percentage point incremental reduction may seem small in absolute terms, but it matters enormously at the individual level. For a patient starting at 113 kg, the difference between 15.6% and 18.7% weight loss is 3.5 kg — close to 8 additional pounds. More importantly, the higher-dose arm significantly outperformed the 2.4 mg arm in achieving ≥20% and ≥25% weight loss thresholds, where the metabolic and cardiovascular benefits are largest and most clinically meaningful.[1]

Why It Matters Clinically

The companion trial, STEP UP T2D, tested the same dose escalation in 512 adults with obesity and type 2 diabetes (mean baseline A1c 8.1%, mean BMI 38.6 kg/m²). In that population, semaglutide 7.2 mg achieved 13.2% weight loss versus 3.9% with placebo (estimated treatment difference −9.3 percentage points; P<0.0001), and also reduced A1c by an additional 1.5 percentage points compared with placebo. The dysesthesia rate in STEP UP T2D was 18.9% with 7.2 mg versus 0% with placebo. Importantly, there was no increase in serious adverse events in either trial, and hypoglycemia rates did not increase in the T2D population despite greater glucose lowering.[1]

The dysesthesia finding — a novel signal not described with semaglutide 2.4 mg — requires attention before the 7.2 mg dose enters wider clinical use. Dysesthesia refers to unpleasant, abnormal skin sensations (tingling, burning, prickling, or crawling feelings). The mechanism is not established. At 22.9% prevalence in the STEP UP population, it is not a rare side effect. Whether it resolves with dose reduction, whether it is linked to the rate of weight loss (and the changes in adipose tissue innervation that accompany it), or whether it is a direct neurological effect of the drug at higher exposure levels — none of this is yet known. Post-marketing pharmacovigilance will be critical.[1, 5]

Limitations

The trial ran for 72 weeks — roughly the same duration as the original STEP trials — without an extension phase, so durability of the incremental weight loss with 7.2 mg versus 2.4 mg beyond 72 weeks is unknown. The dysesthesia signal is novel and its long-term trajectory has not been characterized. The trial population (mean age 47 years, mean BMI 39.9) may not generalize to older adults or patients with more severe obesity who may tolerate dose escalation differently. As a Phase 3b industry-sponsored trial, all analyses were conducted by Novo Nordisk; independent replication has not yet occurred. The semaglutide 7.2 mg dose is not currently FDA-approved.